19. ライソゾーム病 Lysosomal storage disease Clinical trials / Disease details


臨床試験数 : 854 薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-007482-21-GB
(EUCTR)
09/11/200917/08/2009Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET StudyMulti-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET Study Fabry disease with proteinuria.
MedDRA version: 9.1;Level: LLT;Classification code 10018058;Term: Gene genetic abnormality
MedDRA version: 9.1;Classification code 10037032;Term: Proteinuria
Trade Name: perdix
Product Name: perdix
Trade Name: Zestoretic 10,20
Product Name: ZESTORIC
Trade Name: INNOZIDE
Product Name: innozide
Trade Name: lisinopril
Product Name: lisinopril
Trade Name: zestril
Product Name: zestril
Trade Name: coversyl
Product Name: coversyl
Trade Name: coversyl PLUS
Product Name: coversyl PLUS
Trade Name: Accupro
Product Name: Accupro
Trade Name: Accuretic
Product Name: Accuretic
Trade Name: lopace
Product Name: lopace
Trade Name: lopace
Product Name: lopace
Trade Name: triapin
Product Name: triapin& triapin Mite
Salford Royal NHS Foundation TrustNULLNot Recruiting Female: yes
Male: yes
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom